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Interferon Treatment for Chronic Hepatitis C Infection in Hemophiliacs - 
Influence of Virus Load, Genotype, and Liver Pathology on Response 
By John P. Hanley, Lisa M. Jarvis, Janet Andrews, Rosemary Dennis, Peter C. Hayes, Juan Piris, Robert Lee, 
Peter Simmonds, and Christopher A. Ludlam 
In this study, we assessed the effectiveness of interferon 
treatment in 31 hemophiliacs with chronic hepatitis C virus 
(HCV) infection. Interferon alfa-2a (3 MU three times weekly) 
was administered for 6 months. Response was assessed by 
both serial alanine transaminase (ALTI and HCV RNA levels 
measured by a sensitive semiquantitative polymerase chain 
reaction (PCR) method. HCV genotype was determined by 
restriction fragment length polymorphism (RFLPI, and evi- 
dence of changing genotypes during interferon therapy was 
sought. Severity of liver disease was assessed by both non- 
invasive and invasive methods, including laparoscopic liver 
inspection and biopsy. Sustained normalization of ALT lev- 
els occurred in eight patients (2896). and seven (24%) became 
LMOST ALL HEMOPHILIACS who received clotting A factor concentrates before the introduction of effective 
viral-inactivation techniques were infected with hepatitis C 
virus (HCV).’,2 The majority of individuals exposed to the 
virus have become chronic carriers, characterized by both 
persistent fluctuating viremia and variable abnormalities in 
liver function tests. There is a wide spectrum of liver disease 
in these patients, ranging from only minor histologic evi- 
dence of chronic hepatitis to cirrhosis3 and hepatocellular 
~ a r c i n o m a . ~  
Interferon has been used to treat chronic HCV in both 
nonhemophiliacs and hemophiliacs. Response to treatment 
has been assessed by serial serum alanine transaminase 
(ALT) levels, clearance of viremia by polymerase chain reac- 
tion (PCR), and direct assessment of liver histology. Clear- 
ance of viremia is likely to be a prerequisite for a long-term 
response rather than normalization of ALT. To date, there 
have only been a few small studies on the efficacy of inter- 
feron alfa for the treatment of HCV infection in individuals 
with hem~philia.’.~ Some of these studies have suggested 
that the response to interferon in hemophiliacs may be lower 
than in other groups infected with HCV. We report the re- 
sults of interferon therapy in a group of 31 hemophiliacs 
with chronic HCV infection. We have monitored response 
to interferon using a sensitive semiquantitative PCR to detect 
HCV RNA. In addition, we have assessed the extent of liver 
From the Department of Haematology, Royal Injirmary of Edin- 
burgh, Edinburgh; and the Departments of Medical Microbiologj, 
Medicine, and Pathology, and the Medical Statistics Unit, University 
of Edinburgh, Edinburgh, Scotland. 
Submitted June 13, 1995; accepted October 5, 1995. 
Supported by project grants ,from the Medical Research Council 
and Roche Products Limited. 
Address reprint requests to John P. Hanley, MB ChB, MRCP, 
Department of Huemutology, Royal Infrmury of Edinburgh, Lauris- 
ton Place, Edinburgh, EH3 9YW Scotland. 
The publication costs of this article were defrayed in part by page 
charge payment. This article must therefore be hereby marked 
“advertisement” in accordance with 18 U.S.C. section 1734 solely to 
indicate this fact. 
0 1996 by The American SocieQ of Hematology. 
0006-4971/96/8705-0015$3.00/0 
nonviremic as assessed by PCR ( 4 0  HCV/mL). Responders 
universally cleared HCV RNA within 2 months of starting 
interferon. Genotype 3a was associated with a favorable re- 
sponse to interferon. No evidence was found for a change 
in circulating genotype in patients who failed to respond to 
interferon or who relapsed. This study confirms that re- 
sponse rates to interferon are low in hemophiliacs as com- 
pared with other groups with chronic HCV infection. We 
have also demonstrated that virus load measurement over 
the first 8 to 12 weeks of treatment is an extremely useful 
method to identify responders at an early stage. 
0 1996 by The American Society of Hematology. 
disease in these patients using both invasive and noninvasive 
methods, and have critically evaluated whether these investi- 
gations are useful in predicting the response to interferon. 
PATIENTS AND METHODS 
Patient rhuracteristics. A total of 31 patients (30 male and one 
female) were treated (Table 1 ). All patients were anti-HCV-positive 
by Abbott second-generation enzyme immunoassay (A-EIA: Abbott, 
Weisbaden-Dalkenheim, Germany) and were also positive on con- 
firmatory testing by second-generation recombinant immunoblot 
assay (RIBA-2; Chiron Corp, Emeryville, CA) for antibody to non- 
structural proteins 5-1-1 (NS4), c100-3 (NS4). c33c (NS3). and core- 
associated antigen c22-3. 
All had previously received non-virus-inactivated factor concen- 
trates, and 30 of 31 had persistently elevated serum ALT levels 
(ALT levels were measured on 2 3  occasions over the 6 months 
before treatment). Serum ALT level was normal in one individual. 
HCV RNA was detected in all patients by PCR as described below. 
Six patients were anti-HIV-positive (pretreatment CD4 counts, 4, 
20, 140. 180, 250, and 360 celldmm’, respectively), and all were 
HBSAg-negative. In addition, all patients were negative for anti- 
smooth muscle and antimitochondrial antibody and had normal lev- 
els of a-fetoprotein, ceruloplasmin, and (Y 1 -antitrypsin. 
Informed consent was obtained from 
all patients participating in the study. Betore starting interferon treat- 
ment, a detailed assessment was undertaken of the extent of liver 
disease in each patient, with particular reference to the presence o r  
absence of cirrhosis, using both noninvasive and invasive methods. 
The role of invasive investigations in the assessment of liver disease 
was discussed with all patients. Those with anti-FV111 or anti-FIX 
inhibitors were not offered invasive investigations, and individuals 
with von Willebrands disease were not offered liver biopsy. It was 
emphasized that the investigations were not essential for administra- 
tion of interferon but would provide information to counsel the indi- 
vidual as to the extent of liver disease. 
The following investigations were performed after appropriate 
factor concentrate replacement. ( I )  Upper gastrointestinal endoscopy 
was performed in 27 patients to identify the presence or absence of 
esophageal varices. (2) Laparoscopy was performed under sedation 
using a 5-mm pediatric laparoscope (Olympus. Tokyo. Japan) or 
microlaparoscope (Imagyn, Laguna Niguel, CA) in 2 I patients. The 
degree of hepatic inflammation (none, mild. or marked), degree of 
surface fibrosis (none, moderate, or pronounced), and presence of 
cirrhosis and portal hypertension were assessed.“’.” In IS patients, 
a tru-cut biopsy was taken during the laparoscopy. and histology 
was assessed using both the Sheffield scoring system’ (data not 
P retreatment ussrssment. 
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Tabla 1. Patient Characteristics 
Parameter 
No. of 








von Willebrand disease 3 
Total 31 
Age (yr) 35.0 13-67 
Pretreatment ALT (WL) 78 37-175 
Hemophilia B 
Pretreatment HCV RNA (coDies/mL) 106 103->107 
shown) and a visual classification. Using the latter method, overall 
histologic appearance was classified as mild, moderate, or severe. 
(3) Abdominal ultrasound scans to assess liver size, echogenicity, 
and presence of hepatocellular carcinoma, as well as spleen size, 
were performed on 30 patients. Baseline measurements are listed 
in Table 1. In addition, data concerning annual factor concentrate 
consumption and serum Igs (IgG, IgM, and IgA) and serum ferritin 
were collected. 
Interferon alfa-2a (Roche, 
Welwyn Garden City, UK) 3 MU three times per week was given 
subcutaneously. The intention was to treat for 24 weeks. 
Response was 
assessed on the basis of serial monthly ALT levels and HCV RNA 
quantitation. After 6 months’ treatment, a complete ALT response 
(CR) was defined as normalization of ALT (<40 UL) sustained for 
at least 2 months; a partial ALT response (PR) required a more than 
50% reduction in pretreatment ALT. A HCV RNA CR required the 
virus to be undetectable in the serum, ie, PCR-negative ( 4 0  HCVl 
mL, see below); a PR required a 100-fold reduction in HCV RNA 
titer. 
All testing was per- 
formed using serum samples separated within 3 hours of collection 
and stored at -70°C. Virus RNA was extracted from 0.5 mL stored 
sera after pelleting of virus by centrifugation at 100,OOOg for 90 
minutes at 4°C and incubation at 37°C for 2 hours with 1 mg/mL 
proteinase K in the presence of 40 pg/mL polyadenylic acid, 0.5% 
sodium dodecyl sulfate, 0.1 m o m  NaCI, 50 mmoVL Tris hydrochlo- 
ride (pH 8.0). and 1 mmol/L EDTA. RNA was extracted with phenol, 
and after centrifugation the supernatant was reextracted successively 
with phenolkhloroform (1: 1) and chloroform/isoamylalcohol(50: 1). 
Nucleic acid was precipitated by the addition of . I O  vol sodium 
acetate (pH 5.2) and 2 vol ethanol. The dried pellet was resuspended 
in 25 pL diethylpyrocarbonate-treated water.’* RNA was reverse- 
transcribed by nested PCR using 5’ noncoding region-specific prim- 
ers 939, 209, 940, and 211.” For genotyping, product DNAs were 
cleaved with restriction enzymes HaeIIIlRsaI and MvaVHinfI as 
described previo~sly,’~ and the fragments were separated by agarose 
gel electrophoresis using 4% Metaphor agarose (FMC BioProducts, 
Rockland, ME). Subtypes la  and l b  and 2a and 2b were identified 
by the cleavage patterns resulting from digestion with BstUI and 
ScrFI, respectively. I s  Genotyping was performed on all patients be- 
fore starting interferon and after 3 and 6 months’ therapy. 
Virus levels were measured semiquantitatively by limiting-dilu- 
tion analysis of cDNA reverse-transcribed from Centrifu- 
gation of 0.5 mL sera provided a level of detection of approximately 
800 HCVlmL. To increase sensitivity of the PCR method, samples 
Drug dosage and administration. 
Assessment of response to interferon treatment. 
Typing and quantification of HCV RNA. 
that were negative at this level of detection (<800 HCV/mL) were 
further analyzed by centrifugation of 5.0 mL sera, providing a cutoff 
point of approximately 80 HCV/mL. 
The relationships between ALT response or 
HCV RNA response and baseline measurements were assessed using 
Fisher’s exact test for nominal baseline variables, chi-square test for 
trend for ordered categorical baseline variables, Wilcoxon rank-sum 
test for non-normally distributed continuous baseline variables, and 
two-sample t-test for normally distributed continuous baseline vari- 
ables. All significance tests were two-sided. 
Statistical analysis. 
RESULTS 
Of 31 patients, 29 completed 6 months’ treatment with 
interferon. One stopped after 2 months due to leukopenia, 
and one stopped after 5 months due to a subjective hearing 
loss that subsequently recovered. The 29 patients who com- 
pleted 6 months of treatment were evaluated. Normalization 
of ALT (CR) occurred in eight of 29 (28%); a more than 
50% reduction in pretreatment ALT (PR) was achieved in 
four of 29 (14%), and 17 of 29 (59%) were nonresponders 
(NR). Seven of 29 (24%) became PCR-negative for HCV 
RNA (CR). In addition two of 29 (7%) achieved at least a 
lO*-copies/rnL reduction in HCV RNA (PR). In 20 of 29 
(69%), serum HCV RNA levels were unchanged (NR). 
There was a statistically significant difference in age be- 
tween responders (mean age, 46 years) and NR (mean age, 
33 years; two-sample t-test, P = .044). However, multivari- 
ate analysis showed no independent relationship between 
age and response after adjusting for the effect of genotype 
on response (see below). 
Response was not associated with HIV status, body 
weight, seventy of hemophilia, duration of infection, annual 
factor concentrate consumption, serum femtin, or serum IgS 
(data not shown). 
Normaliza- 
tion of ALT levels correlated with clearance of viremia as 
measured by PCR (Spearman rank correlation, r = .53, P = 
.003; Table 2). Of eight patients who had a normalized ALT, 
five also became HCV RNA-negative, whereas in three 
there was no corresponding reduction in virus load. Of four 
patients who achieved a partial reduction in ALT, only one 
became nonviremic. Fifteen of 17 in whom ALT level was 
unchanged also had no change in virus load. Only one indi- 
vidual who had no change in ALT became nonviremic. Me- 
dian ALT values in patients who became nonviremic versus 
those who failed to clear HCV RNA are shown in Fig 1. In 
one patient only, there was a transient HCV RNA clearance 
at 2 months, but at 3 months the HCV RNA titer returned 
to the pretreatment level of lo7 HCV/mL. This was associ- 
Pattems of ALT and HCV RNA responses. 
Table 2. ALT Response and HCV RNA Response 
HCV RNA Response 
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1 1 15 17 
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- 
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Fig 1. Association of virus clearance with normalization of ALT. 
Patients with a partial or no reduction in virus load (line A, n = 22) 
showed no corresponding reduction in ALT, whereas patients who 
became nonviremic (line B, n = 7) achieved a reduction in ALT during 
treatment with interferon. 
ated with a parallel ALT reduction and subsequent relapse 
(Fig 2). There was no relationship between pretreatment 
ALT level and response. 
The rate of 
HCV RNA clearance in seven CR was assessed (Fig 3). In 
six of seven, a prompt reduction in HCV RNA occurred to 
less than the limit of detection within 8 weeks of commenc- 
ing interferon. In one individual (patient no. 2, Fig 3), initial 
clearance of HCV RNA at week 4 was followed by a tran- 
sient increase in virus titer to lo4 copies/mL at weeks 8 and 
12 before sustained clearance between weeks 16 and 24. 
There was 
a striking relationship between HCV genotype and a favor- 
able response to interferon. A total of six of eight hemophili- 
acs infected with genotype 3a became nonviremic. In the 
other 21 patients, only one individual (genotype 2b) became 
HCV RNA-negative (Fisher's exact test, P = .0002). No 
changes in HCV genotype, as detected by RFLP analysis, 
were identified in any patients during interferon therapy (Ta- 
ble 3). 
There was no relationship between pretreatment virus load 
and either response to interferon (Fig 4) or HCV genotype 
(Fig 5). 
Severity of liver disease was assessed by methods outlined 
earlier. Of 28 abdominal ultrasound scans evaluated, five 
(18%) demonstrated splenomegaly and seven (25%) showed 
an abnormal liver (five with hepatomegaly and two with an 
abnormal liver texture). In seven of 25 (28%), esophageal 
varices were demonstrated at endoscopy. Of 20 laparoscopic 
liver inspections, 10 (50%), four (20%), and six (30%) 
showed none, mild, or pronounced surface fibrosis, respec- 
tively, with five patients with pronounced fibrosis having 
Rate of HCV RNA clearance in responders. 
Predictive factors for response to interferon. 
cirrhosis. Inflammation was identified iaparoscopically in all 
patients, being mild in 14 (70%) and marked in six (30%). 
Evidence of portal hypertension was visible in five (25%). 
Liver histology was evaluated in 14 patients and showed 
mild, moderate, and severe (including cirrhosis) histologic 
changes in four (29%), seven (50%), and three (21%), re- 
spectively. 
Analysis of response to interferon against laparoscopic 
liver appearance, liver histology, presence/absence of hepa- 
tomegaly, splenomegaly, and esophageal varices showed no 
evidence that any of these variables were associated with 
response to interferon. 
Within 3 months of discontinu- 
ing interferon, five of seven patients who became nonviremic 
have relapsed, with reappearance of serum HCV RNA and 
elevated ALT levels. In two patients who achieved a partial 
reduction in virus load, HCV RNA levels returned to pre- 
treatment values within 1 month of stopping interferon. Only 
two patients remain HCV RNA-negative with normal ALT. 
The three patients who showed normalized ALT levels with- 
out a corresponding reduction in HCV RNA developed ele- 
vated ALT levels within 2 months of stopping interferon. 
Follow-up information. 
DISCUSSION 
We have shown that the response to interferon therapy in 
hemophiliacs with chronic HCV infection is poor and ap- 
pears inferior to that of other groups of infected patients. In 
this study, only 28% had a normalized serum ALT after 6 
months' treatment with interferon, and 24% became PCR- 
negative for HCV RNA. Furthermore, sustained responses 
were uncommon. This compares with initial ALT CR of 
50% and sustained responses of 20% to 25% reported in 
nonhemophiliacs." Early investigators used ALT to assess 
long-term response. 19,20 More recent studies have confirmed 
that clearance of HCV RNA is a prerequisite for long-term 
response." 
The importance of HCV quantitation has been increas- 
ingly recognized. We describe herein a sensitive semiquanti- 
tative PCR method for HCV RNA detection with a lower 
T 300 6 h  
1 LO 
0 2 4 8 12 16 
Wctks on lntcrfuan 
Fig 2. Breakthrough hepatitis during interferon therapy. This pa- 
tient achieved an initial reaponse to interferon with clearance of HCV 
RNA by week 8 and corresponding reduction in ALT level. As inter- 
feron was continued, viremia recurred by week 12 and there was an 
associated increase in ALT. Such episodes of breakthrough hepatitis 
during interferon treatment may be associated with the development 
of neutralizing antibodies to interferon. 
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Fig 3. Rate of virus clearance in HCV RNA re- 
sponders (n = 7). In 6 of 7 patients who became 
nonviremic, there was a prompt reduction in HCV 
RNA to < the limit of detection within 8 weeks of 
commencing interferon. In one individual (patient 
no. 2)- initial clearance of HCV RNA at week 4 was 
followed by a transient increase in virus titer to 10‘ 
copieslmL at weeks 8 and 12, before sustained claar- 
ance batween weeks 16 and 24. 
‘ ’ i 
2 4 a 12 16 20 24 
Weeks on Interferon 
limit of detection of 80 HCV/mL. This compares with 3.5 
X 10’ equivalentdml when the branched DNA (bDNA) 
assay is used.” Using bDNA, we would have failed to detect 
viremia in four (13%) of our patients and incorrectly classi- 
fied six (20%) as responders who merely showed a partial 
reduction in HCV RNA levels. Clearly, sensitive quantitative 
assays are essential to monitor response to treatment, and 
some studies may have overestimated response rates by us- 
ing relatively insensitive methods for RNA quantitation. We 
found that HCV RNA was cleared within 8 weeks of starting 
interferon in seven patients who responded. Using this 
method, it would therefore be possible to differentiate re- 
sponders from nonresponders at an early stage of treatment 
and discontinue interferon in nonresponders. Alternatively, 
these individuals could be offered a dose-escalation, al- 
though there are few data available in hemophiliacs concem- 
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CR PR NR 
Response - HCV RNA 
Fig 4. Pretreatment virus load and response to interferon. There 
was no significant relationship between pretreatment virus load and 
response to intarferon (2 test for trend, P = ,073). * Fisher‘s exact test. 
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Fig 5. Pretreatment virus load and HCV genotype. There was no 
significant relationship between pretreatment virus load and HCV 
genotype (Kruskal-Wallis test, P = ,771. (0) subtype a; (0) subtype b. 
ing the value of this to increase response rates. In view of 
the generally poor overall responses to interferon in hemo- 
philiacs, we believe this approach is unlikely to benefit a 
significant number of patients. 
In one individual, initial clearance was followed by a tran- 
sient increase in virus titer before further clearance. The 
reasons for this are not entirely clear. Temporary noncompli- 
ance with treatment is a possible explanation, or there may 
be a small number of individuals who achieve a slower 
reduction in HCV RNA rather than the rapid and sustained 
reduction observed in the majority of responders. 
There is usually a good correlation between normalization 
of ALT and HCV RNA clearance in responders to interferon. 
However, discrepancies between ALT and HCV RNA re- 
sponses have been described previously.2’ We have identi- 
fied some individuals who achieved a biochemical response 
without a corresponding reduction in virus load. Clearly, 
these patients are not true responders, and biochemical re- 
lapse is inevitable once interferon is discontinued. Since 
ALT is not an entirely accurate measure of response, studies 
using ALT alone to assess response may also overestimate 
true responders. Interestingly, there was one individual who 
cleared HCV RNA without an associated ALT response. 
This raised the possibility of other non-HCV coexisting liver 
pathology resistant to interferon treatment, but none has been 
identified. Another individual relapsed during interferon 
therapy. Such episodes of “breakthrough hepatitis” are well 
recognized and may be associated with the development of 
neutralizing antibodies to i n t e r f e r ~ n . ~ ~  A change in HCV 
genotype may also be an explanation for breakthrough hepa- 
titis, and a change in the dominant genotype in hemophiliacs 
treated with interferon has been reported.2s In this study, we 
did not detect any changes in the circulating genotype in  
any patients during interferon therapy. However, it  is recog- 
nized that the RFLP method will not detect co-infecting 
genotypes circulating at low frequencies. In addition, inter- 
feron NR may be associated with a change in variants of the 
same genotype (termed quasi-species). Analysis of variants 
within an individual before and after interferon treatment is 
in  progress. 
Several studies assessing response to interferon have been 
performed on cohorts of hemophiliacs infected with HCV.’-‘’ 
Some of these studies have suggested that the overall initial 
response rates are somewhat lower in hemophiliacs than in 
other groups with HCV. Interestingly, response rates in the 
earlier studies are superior to those performed more recently. 
This may be a reflection of the relatively small number of 
patients studied, or may have been caused by progression of 
liver disease in cohorts of hemophiliacs, leading to dimin- 
ished responses to interferon. In addition, although the data 
available provide conflicting results, long-term response ap- 
pears unusual. In the largest study,’ only one of 20 (5%) 
achieved a sustained response to interferon. In the only trial 
that assessed response by liver biopsy,5 four of seven re- 
sponders had a long-term response. Our study, which con- 
tains the largest treated group of hemophiliacs with HCV 
reported to date, supports the view that long-term responses 
to interferon are uncommon in hemophiliacs. Sustained re- 
sponse rates may be improved by longer courses of inter- 
feron. 
Attempts have been made to identify factors that may 
predict response to interferon.”’ Absence of cirrhosis, 
younger age, low serum HCV RNA level, and genotypes 2 
and 3 are all factors associated with a favorable response to 
interferon. As yet, the presence of adverse factors has not 
been considered sufficient to absolutely exclude some indi- 
viduals with HCV from interferon therapy. There has been 
particular concern, in view of the generally poor response 
to interferon in hemophiliacs, that treatment with interferon 
is inappropriate in the majority of individuals. Not only are 
patients exposed to a potentially toxic drug with unpleasant 
side effects, but the cost of a course of interferon is consider- 
able. 
We have tried to identify parameters that inay predict 
response to interferon in hemophiliacs with HCV. Assess- 
ment of liver disease has included both invasive and noninva- 
sive methods. We have shown that genotype 3a is associated 
with a favorable response, but we failed to identify any other 
statistically significant independent variables. including pre- 
treatment virus load, associated with a poor response to inter- 
feron. In view of this. despite the apparent poor response 
to interferon in hemophiliacs, it is not possible to predict 
accurately which individuals are likely to respond. 
In conclusion, the results of interferon treatment for HCV 
in hemophiliacs are disappointing. Interferon alfa-2a 3 MU 
 For personal use only. by guest on January 17, 2014. bloodjournal.hematologylibrary.orgFrom 
INTERFERON FOR HCV IN HEMOPHILIACS 1709 
three times per week for 6 months is unlikely to result in a 
long-term sustained response. Monitoring response with a 
sensitive semiquantitative PCR to quantify HCV RNA is 
extremely useful to identify responders at an early stage 
of treatment. Those who fail to clear HCV RNA should 
discontinue interferon. Dose-escalation is unlikely to benefit 
many patients, but may be attempted in selected individuals. 
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